As of November 8, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Conexeu Sciences Inc. The largest reported stake is Purcell Lynn Sebastian's, at 12.3%. 10 filings are on record since July 20, 2026 (Schedule 13G, August 14, 2026).
Who owns Conexeu Sciences Inc.?
Sell to companies like Conexeu Sciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Jeffrey Sharpe · Sole voting: 1,500,000 · Shared voting: 0 · Sole dispositive: 1,500,000 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-15
- · Reporting person: Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund · Sole voting: 4,314,336 · Shared voting: 0 · Sole dispositive: 4,314,336 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-04
- · Holder: Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund · Percent: 9.99% · SCHEDULE 13G
- · Reporting person: David Bogart · Sole voting: 2,293,750 · Shared voting: 0 · Sole dispositive: 2,293,750 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-18
- · Holder: Jeffrey Sharpe · Percent: 5.4% · SCHEDULE 13D
Conexeu Sciences Inc. has 10 Schedule 13D or 13G filings on record since 2026-07-20. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 12.3% | 3,359,240 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 | |
| 12.1% | 3,276,643 | SCHEDULE 13G, 2026-07-28 | 2026-06-30 | |
| Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | 4,314,336 | SCHEDULE 13G/A, 2026-09-04 | 2026-06-30 |
| 8.1% | 2,293,750 | SCHEDULE 13G, 2026-08-18 | 2026-06-30 | |
| OnePointTwo Capital Ventures LLC | 6.8% | 1,875,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Paisley Capital Holdings Corp | 6.7% | 1,800,000 | SCHEDULE 13G, 2026-07-20 | 2026-06-30 |
| OnePointTwo Capital Ventures II LLC | 5.5% | 1,484,240 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| 5.2% | 1,500,000 | SCHEDULE 13D/A, 2026-09-15 | 2026-09-14 |
Holding shares or following this stake? See who's behind Conexeu Sciences Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Conexeu Sciences Inc. and the records around it.
Conexeu Sciences Inc. elsewhere on the record
- Company profile and every filing Nov 2026
- Form D filing Oct 2026
- Form D filing Sep 2026
- Crowdfunding filing Mar 2026
- Who owns it
Watch Conexeu Sciences Inc.
Get an email when Conexeu Sciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Conexeu Sciences Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Conexeu Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Conexeu Sciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Purcell Lynn Sebastian | 3,359,240 | 0 | 3,359,240 | 0 | SCHEDULE 13G, 2026-08-14 |
| OnePointTwo Capital Performance LLC | 3,359,240 | 0 | 3,359,240 | 0 | SCHEDULE 13G, 2026-08-14 |
| Wright Michael G. | 3,276,643 | 0 | 3,276,643 | 0 | SCHEDULE 13G, 2026-07-28 |
| Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 4,314,336 | 0 | 4,314,336 | 0 | SCHEDULE 13G/A, 2026-09-04 |
| David Bogart | 2,293,750 | 0 | 2,293,750 | 0 | SCHEDULE 13G, 2026-08-18 |
| OnePointTwo Capital Ventures LLC | 1,875,000 | 0 | 1,875,000 | 0 | SCHEDULE 13G, 2026-08-14 |
| Paisley Capital Holdings Corp | 1,800,000 | 0 | 1,800,000 | 0 | SCHEDULE 13G, 2026-07-20 |
| OnePointTwo Capital Ventures II LLC | 1,484,240 | 0 | 1,484,240 | 0 | SCHEDULE 13G, 2026-08-14 |
| Jeffrey Sharpe | 1,500,000 | 0 | 1,500,000 | 0 | SCHEDULE 13D/A, 2026-09-15 |
The latest filing identifies Conexeu Sciences Inc. by CUSIP 20715F100 and gives its principal executive office as Suite 880, 50 West Liberty Street, Reno, NV 89501 (SCHEDULE 13D/A, 2026-09-15).
Source of funds (Item 3)
The information set forth in Items 4, 5 and 6 of this Schedule 13D is incorporated by reference herein. On May 22, 2026, the Reporting Person exercised 500,000 Performance Warrants (the "May 2026 Vested Warrants") that had vested on May 21, 2026, the date of the Issuer's listing on the Nasdaq Stock Market (the "Nasdaq"). The exercise price of the May 2026 Vested Warrants was $0.001 per share, for aggregate proceeds to the Issuer of $500.00. The source of funds used to exercise the May 2026 Vested Warrants was the Reporting Person's personal funds.Jeffrey Sharpe, SCHEDULE 13D/A, 2026-09-15
Purpose of Transaction (Item 4)
Jeffrey Sharpe
The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated by reference herein. Background On May 14, 2025, the Issuer and 1036030 B.C. Ltd., a company solely owned by the Reporting Person, entered into a consulting services agreement pursuant to which the Reporting Person was granted 2,000,000 Performance Warrants to acquire shares of Common Stock at an exercise price of $0.001 per share, with a term of five years. The Performance Warrants vest contingent upon the occurrence of the following four specified performance milestones: - Milestone 1: 500,000 Performance Warrants shall vest upon the Issuer completing and receiving the results of a three-month collagen study conducted in Boston, Massachusetts; - Milestone 2: 500,000 Performance Warrants shall vest upon the Issuer listing its shares of Common Stock on the Nasdaq Stock Market, LLC, or any other recognized stock exchange in North America; - Milestone 3: 500,000 Performance Warrants shall vest upon the Issuer's listed shares of Common Stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater on a recognized North American stock exchange on which the shares of Common Stock are listed; and - Milestone 4: 500,000 Performance Warrants shall vest upon the Issuer's submission of a 510(k) application to the U.S. Food and Drug Administration. On July 8, 2025, Milestone 1 was achieved upon the Issuer completing and receiving the results of the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-07-20 | Paisley Capital Holdings Corp | 6.7% | SCHEDULE 13G |
| 2026-07-28 | Wright Michael G. | 12.1% | SCHEDULE 13G |
| 2026-08-14 | OnePointTwo Capital Ventures LLC | 6.8% | SCHEDULE 13G |
| 2026-08-14 | OnePointTwo Capital Ventures II LLC | 5.5% | SCHEDULE 13G |
| 2026-08-14 | Purcell Lynn Sebastian | 12.3% | SCHEDULE 13G |
| 2026-08-18 | David Bogart | 8.1% | SCHEDULE 13G |
| 2026-08-18 | Jeffrey Sharpe | 5.4% | SCHEDULE 13D |
| 2026-09-04 | Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | SCHEDULE 13G |
| 2026-09-04 | Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | SCHEDULE 13G/A |
| 2026-09-15 | Jeffrey Sharpe | 5.2% | SCHEDULE 13D/A |
Questions about who owns Conexeu Sciences Inc.
Who owns Conexeu Sciences Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Conexeu Sciences Inc.: Purcell Lynn Sebastian (12.3%, Schedule 13G, filed 2026-08-14), Wright Michael G. (12.1%, Schedule 13G, filed 2026-07-28), Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund (9.99%, Schedule 13G/A, filed 2026-09-04), David Bogart (8.1%, Schedule 13G, filed 2026-08-18) and OnePointTwo Capital Ventures LLC (6.8%, Schedule 13G, filed 2026-08-14); 3 more are listed above.
Who are the largest shareholders of Conexeu Sciences Inc.?
By the share each holder's latest filing reports, the largest holders of Conexeu Sciences Inc. on this page are Purcell Lynn Sebastian (12.3%), Wright Michael G. (12.1%) and Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund (9.99%).
When did Purcell Lynn Sebastian buy into Conexeu Sciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Purcell Lynn Sebastian on this page is the Schedule 13G, filed 2026-08-14, reporting 12.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Conexeu Sciences Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Form D, private offering | $22K sold | Form D page | Source |
| November 5, 2026 | Form D, private offering | $5K sold | Form D page | Source |
| October 21, 2026 | Form D, private offering | $1.50M sold | Form D page | Source |
| September 29, 2026 | Form D, private offering | $31K sold | Form D page | Source |
| September 15, 2026 | Form D, private offering | $252K sold | Form D page | Source |
| August 31, 2026 | Form D, private offering | $89K sold | Form D page | Source |
| July 31, 2026 | Form D, private offering | $63K sold | Form D page | Source |
| June 30, 2026 | Form D, private offering | $86K sold | Form D page | Source |
| June 30, 2026 | Form D, private offering | $203 sold | Form D page | Source |
| June 10, 2026 | Form D, private offering | $23K sold | Form D page | Source |
| May 21, 2026 | Form D, private offering | $45K sold | Form D page | Source |
| May 21, 2026 | Form D, private offering | $543 sold | Form D page | Source |
The newest 12 of 24 records.
Conexeu Sciences Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Conexeu Sciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.